undamentalytics Newsletter
Sign in

Traws Pharma, Inc. balance sheet

At the end of fiscal 2025, Traws Pharma, Inc. had total assets of $10.6m, total liabilities of $11.2m and shareholders' equity of −$629,000. It held $3.8m in cash against $0 of debt: net cash of $3.8m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Cash and equivalents382604420214173219553921214
Receivables———020000000024
Total current assets—831044723235182320553923258
Total assets—8410547232351824205539232511
Accounts payable—64435644534686
Deferred revenue (current)—4100000000000—
Total current liabilities—2510108101088106891211
Total debt00000000—000000
Total liabilities—412424131816131214911125711
Shareholders' equity−138−1588023104−125126462811−32−1
Non-controlling interests and other (assets − liabilities − equity)—201——111————————
Net debt (negative = net cash)−3−82−60−44−20−21−4−17−32−19−55−39−21−21−4
Shares outstanding——————————————9m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: EYPT vs TRAWTRAW vs TXMDCPHI vs TRAW

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Traws Pharma, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Traws Pharma, Inc.